News

September 25, 2017

Global, Peer-Reviewed Medical Journal Publishes Results of a First-ever Data Analysis in Irritable Bowel Syndrome (IBS) Patients With Mixed Diarrhea and Constipation (IBS-M), Demonstrating Effectiveness Of the Novel Delivery System of Peppermint Oil in IBgard

Read More

CARET PHARMA TO ACQUIRE FIBER CHOICE®

August 21, 2017

Caret Pharma to Acquire Fiber Choice®, a Line of Innovative Dietary Supplements Containing 100% Natural, Prebiotic Fiber

Read More

IBgard® featured on CBS News: Age Old Remedy Could Spell Relief for IBS

July 5, 2017

IBgard® featured on CBS News: Age Old Remedy Could Spell Relief for IBS

Read More

May 10, 2017

Additional Data Analysis From an IBS (Irritable Bowel Syndrome) Clinical Trial Demonstrate IBgard® Delivered Unprecedented Symptom Reduction in the Largest and Most Dissatisfied Group of IBS Patients

Read More

April 5, 2017

New Medical Research Shows Vitamin D Deficiency Observed in Children, Adolescents and Adults With Irritable Bowel Syndrome (IBS), Calling Attention to Managing Nutritional Requirements Related to IBS

Read More

February 23, 2017

Leading Gastroenterologists Agree That Diagnosing and Managing Irritable Bowel Syndrome (IBS) in Patients With IBS-M (Mixed Diarrhea and Constipation) Remains a Challenging and Difficult to Treat Medical Condition

Read More

December 19, 2016

Real-world Data From Surveillance Study Confirms Excellent Safety and Tolerability Profile of IBgard® at Twelve Months

Read More

December 14, 2016

For Second Consecutive Year, U.S. Gastroenterologists Endorse IBgard® as the #1 Recommended Peppermint Oil for IBS… By Overwhelming Margin

Read More

IBgard brings symptom relief to millions of Canadians

October 26, 2016

IBgard® Brings Symptom Relief to Millions of Canadians Suffering From Irritable Bowel Syndrome (IBS)

Read More

Access to this section is intended for Healthcare Practitioners only.

Please confirm below that you are a Healthcare Practitioner or click here to return to the consumer section of the site.

Confirm